44th week of 2010 patent applcation highlights part 46 |
Patent application number | Title | Published |
20100279846 | PHASE STABLE METAL OXIDE ARTICLE AND PROCESS OF MAKING THE SAME - A shaped ceramic article, made from an amorphous metal hydroxide having a crystalline microstructure and at least 60 weight percent of the crystalline microstructure is tetragonal, is disclosed. The article's crush strength exceeds 4 kg. A process for making the ceramic article is also described. | 2010-11-04 |
20100279847 | SEMICONDUCTOR CERAMIC COMPOSITION - There is provided a semiconductor ceramic composition in which a part of Ba of BaTiO | 2010-11-04 |
20100279848 | PREPARATION METHOD FOR ANION-EXCHANGEABLE, LAYERED DOUBLE HYDROXIDES - The invention has for its object to provide a preparation method for preparing an anion-exchangeable LDH by decarbonation of a carbonate ion type LDH, which makes sure de carbonation is implemented with safety in a continuous manner while crystal shape, crystal structure and crystallinity are kept intact. | 2010-11-04 |
20100279849 | Hydroconversion Multi-Metallic Catalyst and Method for Making Thereof - The invention relates to a bulk multi-metallic catalyst for hydrotreating heavy oil feeds and to a method for preparing the catalyst. The bulk multi-metallic catalyst is prepared by sulfiding a catalyst precursor having a poorly crystalline structure with disordered stacking layers, with a type IV adsorption-desorption isotherms of nitrogen with a hysteresis starting point value of about 0.35, for a sulfided catalyst that will facilitate the reactant's and product's diffusion in catalytic applications. In another embodiment, the precursor is characterized as having a type H3 hysteresis loop. In a third embodiment, the hysteresis loop is characterized as having a well developed plateau above P/P | 2010-11-04 |
20100279850 | CHEMICALLY-RESISTANT COATING COMPOSITION - A coating composition comprising a Photocatalyst Composition comprising a photocatalyst and a pendent silyl ester group, wherein the photocatalyst produces singlet oxygen in the presence of light and ambient air. In certain embodiments, the coating composition further comprises a singlet oxygen scavenger. | 2010-11-04 |
20100279851 | Hydroconversion Multi-Metallic Catalyst and Method for Making Thereof - A catalyst precursor for preparing a bulk multi-metallic catalyst upon sulfidation is provided. The precursor has an essentially monomodal pore volume distribution with at least 90% of the pores being macropores, and a total pore volume of at least 0.08 g/cc. The bulk multi-metallic prepared from the precursor is particularly suitable for hydrotreating heavy oil feeds having a boiling point in the range of 343° C. (650° F.)—to 454° C. (850° F.), an average molecular weight Mn ranging from 300 to 400, and an average molecular diameter ranging from 0.9 nm to 1.7 nm. | 2010-11-04 |
20100279852 | BORON-BASED CATALYSTS - Boron based catalysts and processes for preparing the catalysts are provided. The catalysts are suitable for the alkoxylation of alcohols using alkylene epoxides. | 2010-11-04 |
20100279853 | Hydroconversion Multi-Metallic Catalyst and Method for Making Thereof - A method for preparing a bulk multi-metallic suitable for hydrotreating heavy oil feeds is provided. In the process of preparing the catalyst precursor which is subsequently sulfided to form the bulk catalyst, a catalyst precursor filter cake is treated with at least a chelating agent, resulting in a catalyst precursor with optimum porosity with at least 90% of the pores being macropores, and having a total pore volume of at least 0.12 g/cc. | 2010-11-04 |
20100279854 | Hydroconversion Multi-Metallic Catalyst and Method for Making Thereof - A catalyst and a process for making a catalyst from a precursor composition containing rework materials are disclosed. The catalyst is made by sulfiding a catalyst precursor containing 5-95 wt. % rework material. The catalyst precursor employing rework materials can be a hydroxide or oxide material. Rework can be materials generated in the forming or shaping of the catalyst precursor, or formed upon the breakage or handling of the shaped catalyst precursor. Rework can also be in the form of catalyst precursor feed material to the shaping process, e.g., extrusion process, or catalyst precursor material generated as reject or scrap in the shaping process. In some embodiment, rework may be of the consistency of shapeable dough. In another embodiment, rework is in the form of small pieces or particles, e.g., fines, powder. | 2010-11-04 |
20100279855 | Hydroconversion Multi-Metallic Catalyst and Method for Making Thereof - A stable catalyst with low volumetric shrinkage and a process for making the stable catalyst with low volumetric shrinkage is disclosed. The catalyst is made by sulfiding a catalyst precursor containing at least a Group VIB metal compound; at least a promoter metal compound selected from Group VIII, Group IIB, Group IIA, Group IVA and combinations thereof, having an oxidation state of either +2 or +4; optionally at least a ligating agent; optionally at least a diluent. In the process of making the catalyst, the catalyst precursor is first shaped then heat treated at a temperature of 50° C. to 200° C. for about 15 minutes to 12 hours, wherein the catalyst precursor still has a low (less than 12%) volumetric shrinkage after exposure to a temperature of at least 100° C. | 2010-11-04 |
20100279856 | Hydroconversion Multi-Metallic Catalyst and Method for Making Thereof - A method for preparing a bulk multi-metallic suitable for hydrotreating heavy oil feeds is provided. In the process of preparing the catalyst precursor which is subsequently sulfided to form the bulk catalyst, non-agglomerative drying is employed to keep the catalyst precursor from aggregating/clumping, resulting in a catalyst precursor with optimum porosity with at least 90% of the pores being macropores, and having a total pore volume of at least 0.08 g/cc. | 2010-11-04 |
20100279857 | PRODUCTION METHOD OF PRIMARY AMINES AND CATALYSTS FOR PRODUCING PRIMARY AMINES - A method of producing a primary amine by the hydrogenation of a nitrile in the presence of a hydrogenation catalyst. The hydrogenation catalyst contains at least one metal selected from the group consisting of nickel, cobalt and iron. Before use in the hydrogenation of nitrile, the hydrogenation catalyst is pretreated with at least one treating agent selected from the group consisting of hydrocarbons, alcohols, ethers, esters and carbon monoxide at 150 to 500° C. | 2010-11-04 |
20100279858 | APPARATUS AND PROCESS FOR ACTIVATING A CATALYST - Apparatus for activating a catalyst is described, comprising means for passing high-temperature gases across a catalyst, a primary filter for filtering said gases, means for cooling the filtered gases, and a secondary filter for filtering the cooled gases which collects at least 99.97% of all residual particles smaller than 0.3 μm, wherein the secondary filter is disposable and/or has a design pressure less than 0.5 bar. | 2010-11-04 |
20100279859 | Methods for removing nitrogen compounds from gasoline or diesel fuel using molecularly imprinted polymers - A method and product for removing nitrogen compound molecules from gasoline or diesel fuel includes exposing the gasoline or diesel fuel to a plurality of molecularly imprinted polymer beads (MIPS) that have receptor sites on the surfaces thereof that include imprints that match the physical shape of at least a portion of a nitrogen compound molecule. A quantity of the nitrogen molecules align with and adhere to some of the receptor sites and, accordingly, they are removed from the gasoline or diesel fuel producing a remediated or sweetened gasoline or diesel fuel. According to one embodiment, the MIPS are contained in an enclosure having a plurality of openings large enough to permit the solution to pass through and small enough so as to prevent the MIPS from passing through. According to another embodiment the MIPS are applied (i.e., coated) to the inside surface of a conduit and the gasoline or diesel fuel is forced or allowed to flow through the conduit thereby removing some of the nitrogen molecules therefrom. The MIPS are treated after use to remove a sufficient quantity of the nitrogen molecules from the receptor sites and are reused. | 2010-11-04 |
20100279860 | SUPERABSORBENT POLYMER WITH HIGH PERMEABILITY - The invention relates to absorptive, crosslinked polymers which are based on partly neutralized, monoethylenically unsaturated monomers carrying acid groups wherein the absorptive crosslinked polymer may be coated with a thermoplastic polymer, and have improved properties, in particular in respect of their capacity for transportation of liquids in the swollen state, and which has a high gel bed permeability and high centrifuge retention capacity. | 2010-11-04 |
20100279861 | Antifungal Agents - Novel isoxazolidinone compounds useful in the treatment and/or prevention of human and animal fungal infections, as well as in the control of phytopathogenic fungi in crops are described. Two novel strains of fungi, ATCC No. PAT-7894 and ATCC No. PAT-7895, are disclosed for the preparation of the described isoxazolidinone compounds. | 2010-11-04 |
20100279862 | METHOD FOR WEED CONTROL IN LAWN OR TURF - The invention relates to the use of one or more compounds of the formula (I) or salts thereof, | 2010-11-04 |
20100279863 | HERBICIDAL COMPOUNDS BASED ON N-AZINYL-N'-PYRIDYLSULFONYLUREAS - There are described compounds of the formula (I) | 2010-11-04 |
20100279864 | SAFENING PENOXSULAM HERBICIDE INJURY IN WATER-SEEDED, DIRECT-SEEDED AND TRANSPLANTED PADDY RICE - Clomazone safens rice from the slight amounts of damage caused by penoxsulam at concentrations required to adequately control undesirable vegetation. | 2010-11-04 |
20100279865 | HERBICIDAL COMPOSITION AND METHOD OF USE THEREOF - The present invention relates to a herbicidal composition comprising glyphosate, diquat, prodiamine and ammonium sulfate. The invention also relates to a method of controlling the growth of weeds and to the use of this composition. | 2010-11-04 |
20100279866 | Methods and Compositions for Improving Plant Health - The present invention provides methods and compositions for improving plant health. In particular, application of dicamba or another substrate of DMO, or metabolites thereof including DCSA, to a plant confers tolerance to, or defense against, abiotic or biotic stresses such as oxidative stress including herbicide application, and plant disease, and enhances crop yield. Such application may be in combination with the application of another herbicide such as glyphosate. | 2010-11-04 |
20100279867 | HERBICIDAL FORMULATIONS FOR COMBINATIONS OF DIMETHYLAMINE AND POTASSIUM SALTS OF GLYPHOSATE - A high strength herbicidal composition including: water; glyphosate, predominantly in the form of a combination of dimethylamine salt and potassium salt, in solution in the water in an amount of about 350 grams or greater of acid equivalent per liter of the composition, wherein the composition is formulated to include dimethylamine in an amount to form a salt with about 5% or greater, by weight, of total glyphosate and to include potassium in an amount to form a salt with a percentage of total glyphosate so that the combined sum of glyphosate in dimethylamine and potassium salts is at least 45% of total glyphosate; and optionally, one or more surfactants and/or one or more humectants. | 2010-11-04 |
20100279868 | NOVEL HERBICIDES - Pyrandione, thiopyrandione and cyclohexanetrione compounds of formula (I), which are suitable for use as herbicides. | 2010-11-04 |
20100279869 | Concentrated aqueous phytopathological formulation comprising a herbicide and a betaine type surfactant - The present invention concerns an aqueous phytopathological formulation comprising a hydrosoluble salt of at least one aminophosphate or aminophosphonate type herbicide; at least one principal surfactant selected from alkylbetaines and alkyl(amidoalkyl)betaines, and at least one additive selected from at least one of the following compounds: (i) amines or etheramines comprising at least one hydrocarbon radical containing 2 to 24 carbon atoms, optionally polyalkoxylated; (ii) acid or non acid phosphate mono- or di-esters, optionally polyalkoxylated; and (iii) alkali metal, alkaline-earth metal, ammonium, alkylammonium, alkanolammonium, iron, zinc or manganese salts of a mineral acid. | 2010-11-04 |
20100279870 | METHOD OF PREPARING AMIDOAMINE ALKOXYLATES AND COMPOSITIONS THEREOF - A method of producing an amidoamine alkoxylate is disclosed that involves reacting a triglyceride, a carboxylic acid, or a combination of triglyceride and carboxylic acid with an alkyleneamine to produce an amidoamine and alkoxylating the amidoamine with an alkylene oxide. Also disclosed are amidoamine alkoxylate compositions and their use in agricultural formulations. | 2010-11-04 |
20100279871 | OPTICALLY ACTIVE (R)-ARYLOXYPROPIONIC ACID AMIDES AND HERBICIDAL COMPOSITION COMPRISING SAME - The present invention relates to an optically active (R)-aryloxypropionic acid amide compound which has high selectivity and safety for protecting a crop such as rice, wheat, barley and soy bean, and exhibits excellent herbicidal activity against weeds, and a herbicidal composition comprising the same. | 2010-11-04 |
20100279872 | 4-PHENYLPYRANE-3,5-DIONES, 4-PHENYLTHIOPYRANE-3,5-DIONES AND 2-PHENYLCYCLOHEXANE-1,3,5-TRIONES AS HERBICIDES - Pyrandione, thiopyrandione and cyclohexanetrione compounds, which are suitable for use as herbicides. | 2010-11-04 |
20100279873 | Halogen Alkoxy Spirocyclic Tetramic and Tetronic Acid Derivatives - The invention relates to novel haloalkoxyspirocyclic tetramic and tetronic acid derivatives of the formula (I) | 2010-11-04 |
20100279874 | ARRANGEMENT HAVING A SUPERCONDUCTIVE CABLE - An arrangement is provided having a superconductive cable (SK) which consists of a superconductive conductor ( | 2010-11-04 |
20100279875 | Method for Producing an HTSC Strip - The invention relates to a method for producing a high temperature superconductor (HTSC) from a strip including an upper side precursor layer and which, for continuous sintering of the precursor layer within a furnace in the presence of a fed-in reaction gas, is drawn across a support. A furnace for performing the method is also described. | 2010-11-04 |
20100279876 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES BY COMPARATIVE GENOMIC HYBRIDIZATION - The present invention provides a method of detecting nucleotide sequence differences between two nucleic acid samples. The method employs a comparative genomic hybridization (CGH) technique to analyze the sequence differences between the samples. This method permits the identification of small sequence differences (e.g., sequence divergence of 1% or less) in nucleic acid samples of high complexity (e.g., an entire genome). | 2010-11-04 |
20100279877 | Method for Detection of Melanoma - The present invention provides non-invasive methods for detecting, monitoring, staging, and diagnosing malignant melanoma in a skin sample of a subject. The methods include analyzing expression in skin sample of one or more melanoma skin markers. The melanoma skin markers include IL-1 RI, endothelin-2, ephrin-A5, IGF Binding Protein 7, HLA-A0202 heavy chain, Activin A (βA subunit), TNF RII, SPC4, and CNTF Rα. The skin sample can include nucleic acids, and can be a human skin sample from a lesion suspected of being melanoma. | 2010-11-04 |
20100279878 | Biomarkers for Septic Shock Patients - The instant invention relates generally to the use of IL-8 as a biomarker in septic shock patients as an indicator of the likelihood of survival. The instant invention further relates to the use of IL-8 as a biomarker in septic shock patients for the selection of appropriate therapies. The instant invention further relates to the use of IL-8 as a biomarker for the purposes of structuring, conducting, or evaluating clinical trials or data from clinical trials. | 2010-11-04 |
20100279879 | METHOD FOR THE ANALYSIS OF BREAST CANCER DISORDERS - Method for the analysis of breast cancer disorders, comprising determining the genomic methylation status of one or more CpG dinucleotides in a sequence selected from the group of sequences according to SEQ ID NO. 1 to 10 and/or SEQ ID NO. 50 to SEQ ID NO. 60. Optionally, additionally following steps are performed, the one or more results from the methylation status test is input into a classifier that is obtained from a Diagnostic Multi Variate Model, calculating a likelihood as to whether the sample is from a normal tissue or an breast cancer tissue and/or, calculating an associated p-value for the confidence in the prediction. | 2010-11-04 |
20100279880 | SELF-ENCODING SENSOR WITH MICROSPHERES - A microsphere-based analytic chemistry system is disclosed in which self-encoding microspheres having distinct characteristic optical response signatures to specific target analytes may be mixed together while the ability is retained to identify the sensor type and location of each sensor in a random dispersion of large numbers of such sensors in a sensor array using an optically interrogatable encoding scheme. An optical fiber bundle sensor is also disclosed in which individual microsphere sensors are disposed in microwells at a distal end of the fiber bundle and are optically coupled to discrete fibers or groups of fibers within the bundle. The identities of the individual sensors in the array are self-encoded by exposing the array to a reference analyte while illuminating the array with excitation light energy. A single sensor array may carry thousands of discrete sensing elements whose combined signal provides for substantial improvements in sensor detection limits, response times and signal-to-noise ratios. | 2010-11-04 |
20100279881 | Epitope-mediated antigen prediction - There are many clinical instances in which, during the course of a disease, a patient may produce an antibody directed to unknown protein target(s). The targeted antigen(s) may be autoantigens (e.g., autoimmune diseases), microbial antigens (e.g., infectious diseases), allergens or, as in the case of B lymphoproliferative disorders and monoclonal gammopathies, antigens of unknown identity. When the antigen source is known or suspected, it may be feasible to construct a cDNA expression library and identify it. However, with no clues as to the antigen's origin, expression screening is impossible. We describe a new search strategy to overcome this limitation. We term the approach Epitope-Mediated Antigen Prediction (E-MAP). The technology enables one to link antibodies of unknown specificity to their cognate/target antigens in the protein database without requiring prior knowledge of their cellular source. We also describe a clinical application of the E-MAP technology to the study of multiple myeloma. In this study, we identified the protein target of paraproteins from a number of patients with multiple myeloma. These methods will be useful in biomarker discovery, clinical diagnostics, and therapeutic drug lead identification. | 2010-11-04 |
20100279882 | SEQUENCING METHODS - The present technology relates to molecular sciences, such as genomics. More particularly, the present technology relates to nucleic acid sequencing. | 2010-11-04 |
20100279883 | Probe Design Methods and Microarrays for Comparative Genomic Hybridization and Location Analysis - Methods and systems for identifying and selecting nucleic acid probes for detecting a target with a nucleic acid probe array or comparative genome hybridization microarray, comprising selecting a plurality of potential target sequences, generating a plurality of candidate probes from the target sequences, filtering the plurality of candidate probes by analyzing candidate probes for selected probe properties in silico. Microarrays comprising probes selected by the methods of the invention are particularly useful for comparative genome hybridization and location analysis. | 2010-11-04 |
20100279884 | PRIMERS, PROBES, MICROARRAY, AND METHOD FOR SPECIFIC DETECTION OF NINE RESPIRATORY DISEASE-ASSOCIATED BACTERIAL SPECIES - Provided herein are a primer set capable of amplifying target sequence(s) of nine respiratory disease-associated bacterial species, a probe set specifically hybridizing with the target sequence(s), a microarray comprising the probe set, and a method of detecting one or more of the nine respiratory disease-associated bacterial species using the probe set. | 2010-11-04 |
20100279885 | OLIGONUCLEOTIDE MICROARRAY FOR IDENTIFICATION OF PATHOGENS - A method for detecting a target nucleic acid of a pathogen in a test sample, the method comprising preparing a target nucleic acid detecting reagent and contacting the target nucleic acid detecting reagent with an oligonucleotide microarray. A kit for detecting a target nucleic acid of a pathogen in a test sample is also described. The kit comprises at least one primer pair and an oligonucleotide microarray comprising at least one probe. | 2010-11-04 |
20100279886 | TWO-DIMENSIONAL PHOTONIC BANDGAP STRUCTURES FOR ULTRAHIGH-SENSITIVITY BIOSENSING - The present invention relates to two-dimensional photonic crystal arrays and their use in biological sensor chips, including those in the form of microfluidic devices. Methods of making the two-dimensional photonic crystals and biological sensor chips are described herein, as are uses of these devices to detect biological targets in samples. | 2010-11-04 |
20100279887 | NONLINEAR MAGNETOPHORETIC SEPARATION OF BIOLOGICAL SUBSTANCES - A method of separating a target biological analyte from a mixture of substances in a fluid sample employs nonlinear magnetophoresis. Magnetic particles having the capacity to bind to the target analyte are contacted with the fluid sample so that the analyte is immobilized on the surface of at least some of the particles. The magnetic particles are provided adjacent an array of micromagnets patterned on a substrate so that the particles are attracted the micromagnets. The magnetic particles are then subjected to a traveling magnetic field operating at or above a frequency effective to sweep those particles not bound to analyte to an adjacent micromagnet. Those magnetic particles bound to analyte have a larger size or smaller magnetic moment that prevents them from being moved to adjacent micromagnets, thereby affording separation of the analyte. | 2010-11-04 |
20100279888 | COMPOSITIONS AND METHODS OF DETECTION - The present invention relates generally to the field of diagnostic and detection assays. More particularly, the present invention provides methods and reagents including biochips for detecting the presence of, or distinguishing between, one or more analytes in a sample. | 2010-11-04 |
20100279889 | Population scale HLA-typing and uses thereof - The present invention provides a portable system for real-time population-scale HLA genotyping and/or allelotyping in a field environment and methods of such population-scale HLA genotyping. The individual components of the system are portable to and operable within a field environment thereby providing high throughput with real-time geno- or allelotyping. Also provided are HLA gene-specific primers and HLA allele-specific or single nucleotide polymorphism-specific hybridization probes. In addition the present invention provides a microarray comprising the hybridization probes. Further provided is a kit comprising the HLA gene-specific primers and the microarray. | 2010-11-04 |
20100279890 | FUSION GENE MICROARRAY - The present invention relates to a microarray comprising a chimeric probe for an intergenic exon-to-exon junction of a fusion gene and at least two intragenic probes for a fusion gene partner of the fusion gene. The invention further relates to a method of detecting a fusion gene and a kit suitable for detecting fusion genes. | 2010-11-04 |
20100279891 | Proteome-Wide Quantification of Small Molecule Binding to Cellular Target Proteins - This invention relates to methods for the evaluation and/or quantification of the binding affinity of small molecules or other compounds to target components contained within an analyte, such as target proteins contained within the proteome of a cell or tissue. | 2010-11-04 |
20100279892 | METHODS TO DETERMINE IF A SUBJECT WILL RESPOND TO A BCR-ABL INHIBITOR - Methods are provided for determining if a subject of interest will respond to treatment with BCR-ABL inhibitor, comprising. The method includes quantitating expression of a plurality of genes in CD34+ cells isolated from the subject. Expression of the plurality of genes in the subject of interest is compared to a control. Altered expression of the plurality of genes in as compared to the control indicates that the subject of interest will respond to treatment with the BCR-ABL inhibitor. Arrays are also provided. | 2010-11-04 |
20100279893 | In vitro model of spinal muscular atrophy - A population of iPS cells derived from somatic cells from a spinal muscular atrophy patient is disclosed. In one embodiment of the invention, the cells have been cultured to produce neural cells. In another embodiment, the invention is a method of testing compounds for their ability to modify cellular SMN levels comprising the steps of obtaining a population of iPS cells derived from a spinal muscular atrophy patient or cells derived from the iPS cells, and examining the effect of a test compound on SMN levels. | 2010-11-04 |
20100279894 | BACTERIOPHAGES AND COATING MATERIAL FOR SURFACES - The present invention relates to a composition comprising bacteriophages and coating material for surfaces, characterized in that a first additional peptide is fused on proteins of the bacteriophage and furthermore a second additional peptide is fused on proteins of the bacteriophage. In addition, the present invention relates to a surface that has been coated with the composition and the use of the composition for coating surfaces. | 2010-11-04 |
20100279895 | OLIGONUCLEOTIDE ANALOGUES - The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications. | 2010-11-04 |
20100279896 | siRNA Targeting Interleukin-1 Receptor-Associated Kinase 4(IRAK4) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4. | 2010-11-04 |
20100279897 | Glycine N-methyltransferase (GNMT) Animal model and use thereof - The present invention is a new type of Glycine N-methyltransferase (GNMT) knockout mice model. This model can be applied to screen drug, test of treatment and search for diagnostic marker of hepatocellular carcinoma (HCC), glycogen storage disease, liver dysplasia, fatty liver and other liver disease. | 2010-11-04 |
20100279898 | NORMALIZED NUCLEIC ACID LIBRARIES AND METHODS OF PRODUCTION THEREOF - The present invention relates generally to methods for producing normalized nucleic acid libraries in which each member of the library can be isolated with approximately equivalent probability. In particular, the present methods comprise subtractive hybridization of a nucleic acid library with haptenylated (e.g., biotinylated, avidinated or streptavidinated) nucleic acid molecules that are complementary to one or more of the nucleic acid molecules of the library, such that the variation in the abundances of the individual nucleic acid molecules in the library is reduced. The invention also relates to production of normalized nucleic acid libraries (particularly cDNA libraries) in which contaminating nucleic acid molecules have been reduced or eliminated, and to normalized nucleic acid libraries produced by such methods. | 2010-11-04 |
20100279899 | CAPILLARY ARRAY AND RELATED METHODS - The invention provides methods and devices for detecting the presence of one or more target analytes in a sample employing a channel having affixed therein one or more binding partners for each target analyte. Assays are carried out by transporting the sample through the channel to each successive binding partner so that target analyte present in said sample binds to the corresponding binding partner. The sample is then transported beyond the binding partner(s), followed by detection of any target analyte bound to each binding partner. In one embodiment, binding efficiency is increased by the use of segmented transport, wherein a first bolus or bubble of a fluid that is immiscible with the sample precedes the sample during transport and a second bolus or bubble of a fluid that is immiscible with the sample follows the sample. Many configurations are possible for the device of the invention. A preferred device includes: a substrate with a channel formed in its surface, and a cover element that overlies and seals the channel. Binding partner(s) are affixed to the surface of the cover element facing the channel lumen. | 2010-11-04 |
20100279900 | SOLID SUPPORT COMPRISING A FUNCTIONALIZED ELECTRICITY CONDUCTOR OR SEMICONDUCTOR SURFACE, METHOD FOR PREPARING SAME AND USES THEREOF - The present invention provides a method for encapsulating biocompatible polymers. The method comprises using a solid support comprising at least one electrically conducting and/or semiconducting region containing a reducible oxide on its surface, wherein at least one zone of this surface is functionalized with an electrografted organic film obtained from electroactive organic precursors each comprising at least one functional group of interest, and wherein the number of functional groups of interest accessible for the formation of a covalent, ionic or hydrogen bond with a complementary group within said film represents at least 90% of the total number of functional organic groups of interest, and wherein the density of the accessible functional groups of interest is between 10 | 2010-11-04 |
20100279901 | METHODS FOR PROVIDING STEEL-ON-STEEL FRICTION AND/OR STEEL-ON-PAPER FRICTION WITH LUBRICANT COMPOSITIONS FOR POWER TRANSMITTING FLUIDS - An additive composition may comprise at least one phosphorus- and boron-containing dispersant, at least one boron-containing dispersant, and at least one detergent. Such composition may be useful in power transmissions to provide improved anti-shudder performance and/or improved friction durability. | 2010-11-04 |
20100279902 | LUBRICANT FORMULATIONS AND METHODS - The embodiments described herein relate to particular formulations and methods that provide reduced engine deposits. The lubricant composition includes a base oil having a NOACK volatility of from about 5 to about 15 and a zinc dialkyl dithio phosphate composition. The zinc dialkyl dithio phosphate composition has at least about 65 mole percent of zinc dialkyl dithio phosphate compounds derived from all primary alcohols, wherein the zinc dialkyl dithio phosphate composition has greater than about 40 mole percent zinc dialkyl dithio phosphate compounds having alkoxy moieties derived from alcohols having four carbon atoms. | 2010-11-04 |
20100279903 | Metal Salts Of Oxidized Low Molecular Byproduct Polyethylene As Lubricants For PVC - Polymeric salts, lubricant compositions comprising the polymeric salts and processes for producing such polymeric salts. More specifically, low viscosity lubricants for the working surface of an extrusion die during the processing of plastics that require lubricants to render them processable, such as polyvinyl chloride, chlorinated polyvinyl chloride, polyvinylidene chloride and copolymers thereof. A metal base is reacted with acid functional groups formed during oxidation of a wax, thereby forming a polymeric salt, neutralizing the wax and saponifying saponifiable functional groups. | 2010-11-04 |
20100279904 | ELECTRICAL INSULATING OIL COMPOSITIONS AND PREPARATION THEREOF - An electrical insulating oil composition comprising a heavy reformate as an anti-gassing agent is provided with excellent gassing tendency. In one embodiment, the composition displays a gassing performance of <30 μL per minute as measured according to ASTM D2300-08. In a second embodiment, the composition displays a gassing performance of <0 μL per minute. | 2010-11-04 |
20100279905 | POROUS, DISSOLVABLE SOLID SUBSTRATES AND SURFACE RESIDENT CYCLODEXTRIN PERFUME COMPLEXES - The present invention relates to personal care compositions, especially those personal care compositions in the form of a personal care article that is a porous dissolvable solid substrate. The porous dissolvable solid substrate has a surface resident coating comprising a cyclodextrin perfume complex that can provide a consumer benefit. | 2010-11-04 |
20100279906 | FORMULATIONS COMPRISING AN ANTI-MICROBIAL COMPOSITION - The present invention describes a formulation comprising: (A) at least one surfactant; and (B) an anti-microbial composition that comprises (i) an anti-microbial agent with surfactant properties; (ii) a hydrophobic material and (iii) a polar solvent. | 2010-11-04 |
20100279907 | BOYS HYGIENE PRODUCTS SHAPED LIKE SPORTS BALLS - Hygiene products for boys contain natural ingredients mild to the skin of boys. They have mild natural non-flowery scents. The boys hygiene products are in the shape of simulated sports balls sized to fit into a boys hand. A combination soap and shampoo is formed into a sports ball with a hole through it to receive an elasticized wrist loop therethrough. A boys butterball lotion is in the shape of simulated sports balls rubbed on the skin. A boys stick deodorant has a housing in the shape of a simulated sports ball. Team names and insignia may be applied to the surfaces of the simulated sports balls and the cords. | 2010-11-04 |
20100279908 | ENVIRONMENTALLY RESPONSIBLE PERSONAL CLEANSING COMPOSTIONS WITH HIGH PERFORMANCE - A method is provided for formulating a personal cleansing composition. At least one primary surfactant, at least one secondary amphoteric and/or nonionic surfactant, at least one humectant, and at least one polymeric and/or quaternary conditioner are selected, each of these components having a natural and renewable resource origin. The primary and secondary surfactants are combined with the at least one humectant and the at least one conditioner in a final composition that includes the combined primary and secondary surfactants at less than about 14 wt. %, and includes the combined at least one humectant and at least one conditioner at less than 5.5 wt. %. After forming the final composition, an optimum performance index (OPI) is determined for the composition to ensure that the composition has an OPI of at least about 5.450. The OPI is calculated as: OPI=3÷((solids wt. %+Zein score)÷performance grade). | 2010-11-04 |
20100279909 | Skin Cleansing Formulations With Silica Particle Sensory Indicator - A composition comprising surfactant, structuring agent, glycerin, and a silica particle that disintegrates during use. Also, a method comprising applying the composition to hands; rubbing the hands together until a sensory change detectable to the hands is perceived; and rinsing the hands with water. The composition provides a signal to a user to continue washing for a sufficient time. This silica particle disintegrates to a size that is not felt by a user, and this indicates to the user that there has been a sufficient time for washing. | 2010-11-04 |
20100279910 | METHOD FOR MAKING A PHOTORESIST STRIPPING SOLUTION COMPRISING AN ORGANIC SULFONIC ACID AND AN ORGANIC HYDROCARBON SOLVENT - An improved method for making a photoresist stripping solution for a metal-containing semi-conductor substrate where the stripping solution comprises a blend of at least one organic sulfonic acid with a halogen-free hydrocarbon solvent wherein concentrations of trace amounts of residual sulfuric acid and sulfur trioxide in the blend are reduced to very low levels. | 2010-11-04 |
20100279911 | ANTI-GRAFFITI TREATMENT - The invention relates to the use, in anti-graffiti treatments, and preferably in graffiti-suppressing treatments, of a particular dicarboxylic acid diester having improved treatment efficiency. | 2010-11-04 |
20100279912 | Water Based Paint Thinner - A paint thinner and cleaner includes a methyl soy ester and dibasic ester and satisfies a less than 25 grams per liter Volatile Organic Compound (VOC) rating which permits the thinner and cleaner to be used for cleaning and thinning in government regulated areas. Requirements for reducing VOCs are well recognized. The paint thinner and cleaner of the present invention performs as well as products (for example, hydrocarbon based thinners) having greater than 25 grams per liter VOC products. Further, the paint thinner and cleaner according to the present invention has less than one tenth of the hazardous ingredients present in the other paint thinners. The paint thinner and cleaner is suitable for reducing water and oil based coatings and material. | 2010-11-04 |
20100279913 | Compositions - A water-soluble package comprising at least two water-soluble bodies, preferably detergent compositions, wherein the at least two bodies are not adhered to each other by an adhesive and are retained in positions relative to one another by a water-soluble film surrounding the bodies. These bodies have good dissolution properties in water and are dimensionally stable. | 2010-11-04 |
20100279914 | COATED DETERGENT COMPOSITION AND MANUFACTURE PROCESS - The present invention relates to a coated detergent composition and a process of manufacturing thereof. More in detail the present invention refers to a coated detergent tablet wherein the coating is applied to the tablet by bringing a powder coating material in direct contact with the tablet and thereafter equalizing the powder particles in a way that a homogenous “fused” coating (film) layer is obtained. | 2010-11-04 |
20100279915 | POLYPEPTIDES HAVING LIPASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME - The present invention relates to a new wild-type lipase, its nucleic acid sequences and the amino acid sequences thereof. This new lipase shows washing performance in the form of wild-type. The present invention also relates to the method for producing the lipase and the uses of the lipase in baking. | 2010-11-04 |
20100279916 | FABRIC SOFTENING COMPOSITIONS COMPRISING POLYMERIC MATERIALS - Fabric softening compositions comprising polymeric materials capable of retaining volatile perfume ingredients are disclosed, as well as methods of softening fabrics. | 2010-11-04 |
20100279917 | SUBSTITUTED OCTANE(ENE) NITRILES, METHODS FOR THE SYNTHESIS THEREOF AND USES THEREOF IN PERFUMERY - Compounds of general formula (I) below: | 2010-11-04 |
20100279918 | Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents - A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described. | 2010-11-04 |
20100279919 | COMPOSITIONS COMPRISING HUMAN INTEGRIN-LINKED KINASE-SIRNA AND METHODS OF USE THEREOF - The present invention provides nucleic acid molecules that inhibit ILK expression. Methods of using the nucleic acid molecules are also provided. | 2010-11-04 |
20100279920 | CRITICAL CARE PRODUCT FOR NEONATAL CALVES - A product and method for treating dehydration in neonatal calves. The product is administered to dehydrated calves during treatment, to the exclusion of milk replacers or electrolytes. | 2010-11-04 |
20100279921 | IMPAIRED WOUND HEALING COMPOSITIONS AND TREATMENTS - Methods and compositions comprising combinations and uses of a first anti-connexin agent and a second anti-connexin agent, for example, one or more anti-connexin polynucleotides and one or more anti-connexin peptides or peptidomimetics, are provided for therapeutic use including uses for the promotion and/or improvement of wounds and wound healing and/or tissue repair. | 2010-11-04 |
20100279922 | Melanocortin Receptor Ligands - The present invention is directed to compounds according to formula, | 2010-11-04 |
20100279923 | THERAPEUTIC APPLICATION OF KAZAL-TYPE SERINE PROTEASE INHIBITORS - The subject of the present invention is, in the most general aspect, the therapeutic application of the Kazal-type serine protease inhibitor Infestin or domains thereof or modified Kazal-type serine protease inhibitors based on Infestin homologs, which prevent the formation and/or stabilization of three-dimensional arterial or venous thrombi by interfering with proteins involved in activation of the so-called intrinsic coagulation pathway. In particular the present invention relates to the use of said Kazal-type serine protease inhibitors or fragments thereof or modified Kazal-type serine protease inhibitors, in the treatment or prophylaxis of a condition or disorder related to arterial thrombus formation, i. e. stroke or myocardial infarction, inflammation, complement activation, fibrinolysis, angiogenesis and/or diseases linked to pathological kinin formation such as hypotonic shock, edema including hereditary angioedema, bacterial infections, arthritis, pancreatitis, or articular gout, Disseminated Intravasal Coagulation (DIC) and sepsis. | 2010-11-04 |
20100279924 | PEPTIDES AND PEPTIDE DERIVATIVES AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - Therapeutic compositions can include modified peptides which are derived from the chain of the Bbeta(15-42)-fibrin fragment and wherein one or several of the amino acids of the sequence have been substituted by genetically encoded or not genetically encoded amino acids or peptidomimetics. They may exist as free peptides or as C-terminal derivative and/or being linked to a polyethylene glycol (PEG)-polymer, and have anti-inflammatory and/or endothelium stabilizing effects. Esters or amides may for instance be taken into consideration as C-terminal derivatives. Processes for production of the peptides and derivatives thereof are also described. | 2010-11-04 |
20100279925 | Airway Administration of Site-Inactived FVIIA in Inflammatory Conditions Affecting the Respiratory Tract - The present invention provides methods for the local treatment of acute and chronic extravascular pulmonary fibrin deposition and/or reducing unwanted effects associated with systemic administration of natural anticoagulants to a subject via airway administration to the subject by intratracheal, intrabronchial or intraalveolar routes of site-inactivated FVIIa or biologically active derivatives thereof. | 2010-11-04 |
20100279926 | Compositions and Methods for Treating Atherosclerosis - Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided. | 2010-11-04 |
20100279927 | GROWTH FACTOR COMPLEX - An isolated protein complex is provided which includes a growth factor, growth factor binding protein and vitronectin. Preferably, the isolated protein complex includes an insulin-like growth factor-I, insulin-like growth factor binding protein-3 or insulin-like growth factor binding protein-5 and vitronectin. Also provided are methods of modulating cell proliferation and/or migration by administering said protein complex for the purposes of wound healing, skin repair and tissue replacement therapy. Conversely, by using agents that disrupt growth factor protein complexes formed in vivo, growth factor-driven cell proliferation and/or migration may be suppressed such as for the purposes of treating cancers, psoriasis, atherosclerosis and wounds prone to hypertrophic scarring. | 2010-11-04 |
20100279928 | SLDLR IN VIRAL HEPATITIS - The invention relates to the use of the souluble LDL receptor (sLDLR) in viral hepatitis. | 2010-11-04 |
20100279929 | Novel bacillus thuringiensis gene with coleopteran activity - The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of | 2010-11-04 |
20100279930 | HUMAN PANCREATIC POLYPEPTIDE (HPP) ANALOGUES AND THEIR EFFECTS ON FEEDING BEHAVIOUR - Analogue of human Pancreatic Polypeptide which differs from native human pancreatic polypeptide in respect of amino acid substitutions at one or more residues; and also uses of one or more of said compounds, methods that use one of more of said compounds, compositions comprising one or more of said compounds; and methods of making said compounds. | 2010-11-04 |
20100279931 | Insulin Derivative - The present invention relates to novel human insulin derivatives which are soluble at physiological pH values and have a prolonged profile of action. The invention also relates to pharmaceutical compositions containing such derivatives and to methods of treating diabetes and hyperglycaemia using the insulin derivatives of the invention. | 2010-11-04 |
20100279932 | BINDING CONSTRUCTS AND METHODS FOR USE THEREOF - The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins. | 2010-11-04 |
20100279933 | VEGF ANTAGONIST FORMULATIONS - Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4. | 2010-11-04 |
20100279934 | TOPICAL COMPOSITIONS FOR DELIVERY OF PROTEINS AND PEPTIDES - Aspects of this invention relate to compositions and methods for the stabilization, storage, and delivery of biologically active agents, in particular peptides and nucleic acids. Particularly preferred embodiments include compositions that comprise a recombinant naturally occurring human hepatocyte growth factor (HGF), such as dHGF, a five amino acid truncated HGF variant, and at least one monoglyceride that remains in crystalline form at body temperature. Optionally, a gelling agent such as, hydroxyethylcellulose, and/or an antipathogenic compound (e.g., bupivacaine) can be included in the composition. Methods of use of these compositions to improve, ameliorate, or treat skin conditions are also embodiments. | 2010-11-04 |
20100279935 | COMPOSITIONS FOR INDUCING LABOR AND ASSOCIATED METHODS - The invention discloses a pharmaceutical composition containing oxytocin and melatonin in amounts therapeutically effective for inducing labor in a pregnant human patient. Preferably, the oxytocin content is reduced to mitigate unwanted side effects and the melatonin content synergistically enhances the oxytocin's labor-inducing effectiveness. Also disclosed is a pharmaceutical composition for treatment of a pregnant human patient experiencing pre-term labor characterized by early expression of melatonin receptors in myometrial cells, the composition containing one or more agents which interfere with melatonin binding to said receptors. Additionally, the invention includes a method of treatment effective in inducing labor in a pregnant human patient, the method comprising coadministering melatonin and oxytocin to the patient and a method of treating pre-term labor in a pregnant human patient manifesting early expression of melatonin receptors in her myometrial tissues, the method comprising administering to the patient an agent effective in blocking melatonin binding to the receptors. | 2010-11-04 |
20100279936 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES - The invention relates to novel compounds according to formula Ia and Ib; (Formula Ia and Ib) wherein A represents substituted or unsubstituted C | 2010-11-04 |
20100279937 | Method of Inhibiting Angiogenesis, Tumorigenesis and Cathepsin Activity - Insulin-like growth factor binding proteins (IGFBPs) and variants thereof, including IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-6 and the C-terminal fragments thereof, inhibit angiogenesis, tumorigenesis and cathepsin activity, particularly cathepsin B activity. | 2010-11-04 |
20100279938 | Platelet Promoting Protein and The Usage Thereof - The present invention discloses a protein that has strong affinity to thrombopoietin receptor (C-MPL) and the nucleotide sequences of the protein. The protein is capable of increasing the numbers of platelets and enhancing the blood clotting in vivo and is named as platelet promoting protein (PPP). The protein and its nucleotide sequences can be used for the treatment of blood diseases including thrombocytopenia. | 2010-11-04 |
20100279939 | RECOMBINANT HUMAN FIBRINOGEN FOR TREATMENT OF BLEEDING IN TRAUMA AND PLATELET DISORDERS - The present invention provides methods of using recombinant human fibrinogen to prevent or treat excessive bleeding in pre-hospital and hospital settings. In particular, the present invention relates to methods for treating bleeding using recombinant human fibrinogen in individuals suffering from traumatic hemorrhages in pre-hospital settings and in individuals having thrombocytopenia or qualitative platelet disorders. | 2010-11-04 |
20100279940 | CHIMERIC OSTEOGENIC FACTOR CONTAINING PROTEINS CAPABLE OF INCREASED NUCLEAR LOCALIZATION AND METHODS OF USE THEREOF - Compositions comprising osteogenic factors fused with membrane transduction domains of viral proteins are provided. Also provided are methods of expression and use of such compositions. Further, the methods of making such compositions are also provided. The methods involve transfecting the cells with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter and optionally a membrane transduction domain of a viral protein. Transfection may be accomplished ex vivo or in vivo by direct injection of virus or naked DNA, or by a nonviral vector such as a plasmid. Methods for treating disc disease associated with trauma or disc degeneration are also described. | 2010-11-04 |
20100279941 | CD36 MODULATION AND USES THEREOF - Methods, uses, kits and products are described for the prevention and treatment of ischemia-associated cardiopathies such as myocardial ischemia/reperfusion (I/R) injury, based on the selective modulation of CD36. | 2010-11-04 |
20100279942 | METHODS FOR TREATING MOTOR NEURON DISEASE - An object of the present invention is to provide an agent effective for the treatment and/or prevention of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The present invention provides a therapeutic and/or preventive agent for motor neuron disease comprising the following oligopeptide shown in any of (a) to (c) or a pharmaceutically acceptable salt thereof as an active ingredient: (a) an oligopeptide consisting of the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1); (b) an oligopeptide consisting of an amino acid sequence having a deletion, substitution, insertion, or addition of one or several amino acids in Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death caused by a mutant superoxide dismutase-1 gene; and (c) a modified oligopeptide from the oligopeptide (a) or (b). | 2010-11-04 |
20100279943 | CYTOPLASMIC MALATE DEHYDROGENASE (MDH1) TARGETED TREATMENT FOR NEURODEGENERATIVE DISEASES - The present invention provides compositions for treating neurodegenerative diseases, including ALS, involving complex formation of cytosolic malate dehydrogenase with certain neurodegenerative disease-causing proteins, comprising an agent capable of reducing an interaction between a malate dehydrogenase protein and a conformationally altered or mutant protein associated with a neurodegenerative disorder, including mutant SOD1 protein. The present invention also provides methods of identifying an agent capable of treating such disorders, including ALS, comprising testing agents for the ability to disrupt or prevent formation of a malate dehydrogenase complex with a conformationally altered or mutant protein associated with a neurodegenerative disorder, including MDH-mutant-SOD1 complex, and methods of treating neurodegenerative disorders. | 2010-11-04 |
20100279944 | SUPPRESSION AND TREATMENT OF NEUROPATHIC PAIN - The invention provides a method for suppressing the development of or treating neuropathic pain in a subject comprising administering to the subject an effective amount of a peptide of the formula: X | 2010-11-04 |
20100279945 | High-potency botulinum toxin formulations - The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD | 2010-11-04 |